Highlights Island Pharmaceuticals Limited

Equities

ILA

AU0000138869

Market Closed - Australian S.E. Other stock markets 00:51:57 2024-05-17 EDT			5-day change	1st Jan Change
0.065 ^AUD	+3.17%		+10.17%	-31.58%

05-08	Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13%	MT
04-16	Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Island Pharmaceuticals Reallocates Grant Funding to Dengue Fever Trial; Shares Rally 13%	05-07	MT
Island Pharmaceuticals Reports Positive Data from Dose Study of Dengue Medication	04-16	MT
Island Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-25	CI
Island Pharmaceuticals Announces Change of Company Secretaries	11-30	CI
Island Pharmaceuticals Gets Nearly AU$390,000 R&D Tax Rebate; Shares Fall 4%	11-09	MT
Island Pharmaceuticals Receives Ethics Approval for Ascending Dose Study	11-06	MT
Island Pharmaceuticals Secures Australian Patent for Flavivirus Treatment	11-02	MT
Island Pharmaceuticals Secures US Patent to Support Dengue Medication	23-09-13	MT
Island Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Island Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Island Pharmaceuticals Ltd Receives Additional FDA Feedback on IND for ISLA-101 Phase 2a Clinical Study	23-01-31	CI
Island Pharmaceuticals Receives US FDA Feedback for Upcoming Phase 2 Dengue Trial; Shares Fall 5%	23-01-20	MT
Island Pharmaceuticals Submits IND Application to US FDA for Clinical Trial of Dengue Fever Drug Candidate	22-12-27	MT
Island Pharmaceuticals Submits Investigational New Drug Application for ISLA-101 Clinical Trial	22-12-27	CI
Island Pharmaceuticals Limited Announces Institutional Review Board Approval Receive for ISLA-101 Phase 2A Clinical Trial	22-12-14	CI
Island Pharmaceuticals Limited Provides Positive Analytical Results for ISLA-101 Capsules	22-11-13	CI
Island Pharmaceuticals Ltd Provides Update Regarding the Isla-101 Clinical Trial Product Manufacturing Campaign for the Company's Phase 2A Clinical Trial	22-10-27	CI
Island Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-25	CI
Island Pharmaceuticals : Quarterly Activity Report & Appendix 4C	22-07-27	PU
Island Pharmaceuticals Hires US Contract Manufacturer to Produce Antiviral Drugs for Dengue Trial	22-06-15	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Island Pharmaceuticals Limited

Equities

ILA

AU0000138869

Highlights

Filters